About – Douglas Berger Psychiatrist Tokyo

Dr. Douglas Berger, M.D., Ph.D., Meguro Counseling Center Director

Dr. Berger came to Japan as a medical exchange student and psychiatric researcher at the Tokai University School of Medicine on a research fellowship from the Matsumae International Foundation. He later returned to Japan to do further psychiatric research at the Tokyo University Department of Psychosomatic Medicine and the Tokyo Institute of Psychiatry. Dr. Berger speaks native-level Japanese and regularly conducts psychotherapy for mixed-cultural couples as well as the local Japanese community. This page lists Dr. Berger’s research activity, and this page is an archive of community education articles for the Tokyo Families Magazine written by Dr. Berger. Dr. Berger also works extensively with children as Director of the Tokyo Child & Adolescent Counseling Service. Dr. Berger is a legal permanent resident of Japan.

Douglas Berger is a now a fully bilingual American board certified psychiatrist, is the Director of the Tokyo Meguro Counseling Center. Douglas Berger is a M.D., and a Ph.D. Dr.  Berger is a graduate of New York Medical College where he completed a 4-year residency program in psychiatry. He then finished a fellowship in Psychosomatic Medicine at the Albert Einstein College of Medicine. Now based in Tokyo, he had served on the Faculty of the Albert Einstein College of Medicine Department of Psychiatry in New York as an Assistant Professor of Psychiatry and licensed practicing U.S. physician. Dr. Berger’s Japanese qualifications include a Ph.D. from the University of Tokyo School of Medicine received for psychiatric research done while at the Tokyo University Department of Psychosomatic Medicine.

Credential Verifications

Dr. Berger’s medical degree is from the United States, he is well-versed in the use of psychiatric medication and can guide the use of psychiatric medications integrated with psychotherapy through the physicians affiliated with his counseling practice (he does not directly practice medical care in Japan). Further information on Dr. Berger can be seen on his personal home page.

Publications by Dr. Douglas Berger, psychiatrist in Tokyo

Berger D: DOUBLE BLINDING REQUIREMENT FOR VALIDITY CLAIMS IN COGNITIVE-BEHAVIORAL THERAPY INTERVENTION TRIALS FOR MAJOR DEPRESSIVE DISORDER. Analysis of Hollon S, et al., Effect of cognitive therapy with antidepressant medications vs antidepressants alone on the rate of recovery in major depressive disorder: a randomized clinical trial, F1000Research 2015, 4:639 (doi: 10.12688/f1000research.6954.1). U.S. National Library of Medicine version.

Berger D: DOUBLE-BLINDING AND BIAS IN MEDICATION AND COGNITIVE-BEHAVIORAL THERAPY TRIALS FOR MAJOR DEPRESSIVE DISORDER, F1000Research 2016, 4:638 (doi: 10.12688/f1000research.6953.2). U.S. National Library of Medicine version.

Articles by Douglas Berger, M.D., Ph.D. for Tokyo Families magazine.

Click here to see a full list of articles.

For more information on Dr. Doug Berger, read some of the articles here.

To contact Douglas Berger psychiatrist Tokyo and set up an appointment, click here.

Dr. Gibbons says psychotherapy has evidence: https://t.co/zU0kSJykmp None have double-blinded trials, blind assessments only record unblinded data, and placebo effect is unfilterable with subjective endpoints in unblinded non-inferiority studies. https://t.co/2opApRuwKL #li

The authors own patents on botulinum toxin (BT) for depression/anxiety by facial muscle injection: https://t.co/xMpQbzg2Gy They promote facial injections as the patents are only for these muscles while BT affects the brain injected from many places. https://t.co/tReJReVhnP #li

S Hollon trying to wriggle-out of the need for double blinding and blind placebo control in psychiatric studies with SUBJECTIVE endpoints https://t.co/DkJ7w4TPhN. Quoting Churchill on democracy has nothing to do with treatment of a human condition. See https://t.co/pCdesvYiey

Dr. Byatt makes the point to continue bupropion in this 14wk pregnant patient as she is already exposed for the first trimester: https://t.co/krUSUTsP8t Why Dr. Byatt does not recommend trying to find the lowest effective dose though is baffling. https://t.co/4EE55E1tzZ #li

The open-label GeneSight and unblined/no-blind placebo Genomind studies are at high-risk for researcher bias and should be suspect to extreme caution: https://t.co/y0WTC42zXm Us: https://t.co/f7ZtKavHEq

Load More...

Blue-blocking glasses for mania? https://t.co/vmAOFTUtGb only 11-12 subjects in each group in a single blind (not double-blind) study, only followed for one week. Poorly controlled studies should not have results exaggerated. https://t.co/lABkWI4nXZ

Depression studies have subjective endpoints so that double blind/blind placebo are needed for efficacy: https://t.co/4XySe7dNmt Hope makes all improve on non-inferiority. "Blind assessments" are deceptive as all the subjects and treaters are UNblind. https://t.co/K6iHnNBhQ1

This study https://t.co/1mfQHq3VWs quoted the parents of a 6 year-old who heard their child's voice. They concluded “The voice and image kept him alive" though It could also be a neurological echo of an emotional memory. Psychodynamics are conjecture. https://t.co/RZFx8zOZJO

Genetic tests are expensive: https://t.co/P4nDSdXfE9. Whether “adverse effects” are due to slow metabolism vs. illness are easily studied: crushed Pills can be blindly put in juice. Do this on and off and see which days correspond to symptoms. Us: https://t.co/1HKbrH9Y6i

Pts given 2-mos of CBT-ib (insomnia/bipolar): https://t.co/Gp5qCz4P7h. Dr. Aiken states to give the “expectation..they..deserve a full remission.” But giving expectations to an unblinded cohort w/no placebo control is the exact thing to avoid. https://t.co/UKcXpxJdqE

Load More...